Business

Announcement on Voluntary Disclosure of the Latest Data of Suvozertinib as First-Line Treatment for EGFR PACC or Other Rare Mutant Non-Small Cell Lung Cancer Released at the 2026 European Lung Cancer Conference (ELCC)

Announcement on Voluntary Disclosure of the Latest Data of Suvozertinib as First-Line Treatment for EGFR PACC or Other Rare Mutant Non-Small Cell Lung Cancer Released at the 2026 European Lung Cancer Conference (ELCC)

articleDizal (jiangsu) Pharmaceutical Co. Ltd. Class AMarch 27, 20265/news/announcement-on-voluntary-disclosure-of-the-latest-data-of-suvozertinib-as-first-line-treatment-for-egfr-pacc-or-other-rare-mutant-non-small-cell-lung-cancer-released-at-the-2026-european-lung-cancer-conference-elcc
Announcement on Voluntary Disclosure of the Latest Data of Suvozertinib as First-Line Treatment for EGFR PACC or Other Rare Mutant Non-Small Cell Lung Cancer Released at the 2026 European Lung Cancer Conference (ELCC)

About this update from Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A

Announcement on Voluntary Disclosure of the Latest Data of Suvozertinib as First-Line Treatment for EGFR PACC or Other Rare Mutant Non-Small Cell Lung Cancer Released at the 2026 European Lung Cancer Conference (ELCC) The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A